Literature-reported activity
| Endpoint | Reported result | Experimental context | Source location |
|---|---|---|---|
| FGFR2 degradation DC50 | 231.7 nM | KATO III cells, 12 h; Western blot; average of two independent experiments, each containing two biological replicates | Main Fig. 4C, p. 6 and section 2.5 |
| Antiproliferative IC50 | 65.49 nM | KATO III cells; CCK-8 assay, 96-h incubation followed by 2-h CCK-8 development (section 4.4); drug-addition timing is not explicitly detailed in the method | Main section 2.6 and Fig. 5D/E; proliferation method section 4.4 |
| Isoform selectivity | FGFR2 and FGFR1 degradation; no detectable FGFR3/4 degradation under tested conditions | 300 or 1000 nM, 6 h; H1581, KATO III, RT112 and Hep3B cell models | Main section 2.8, Fig. 7 |
Evidence limits
- DCAF16 knockdown attenuated LC-MG-5-mediated FGFR2 loss; direct covalent target-site mapping and comprehensive proteomic selectivity were not established.
- In vivo antitumour efficacy was not established.
- Literature assay results do not establish DC stock, purity, formulation or supply lead time.
These values are reported in the cited research and depend on the experimental conditions. DC Chemicals supplies research compounds; literature results are not guaranteed product performance.
Reference
Cao X, Huang X, Song C, Shi S, Zhu Y, Zheng L, Liang G, Chen L. Converting FGFR inhibitors into selective covalent molecular glue degraders via transposable gluing handles. European Journal of Medicinal Chemistry (2026), 119034. DOI: 10.1016/j.ejmech.2026.119034.
Identity & specifications
| Product name | LC-MG-5 |
| Synonyms | LC MG 5; LCMG5; FGFR2 molecular glue LC-MG-5 |
| Molecular formula | C26H29Cl2N7O5S |
| Molecular weight | 622.54 |
| Structure / form | Neutral parent; no counterion assigned |
| Stereochemistry | No stereocentres |
| SMILES | C=CS(=O)(=O)N1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1 |
| CAS | Not assigned |
| Supply assessment | Request synthesis assessment |
| Purity / storage / specifications | To be confirmed for the supplied batch |
Molecular formula and molecular weight were calculated from the verified structure. Literature sample purity is not a specification for a DC Chemicals batch.
Product documents
Contact us to confirm available specifications and documentation for your requested material. A batch-specific COA is available only for a released batch.
Ask about specifications and documentsCao X, Huang X, Song C, Shi S, Zhu Y, Zheng L, Liang G, Chen L. Converting FGFR inhibitors into selective covalent molecular glue degraders via transposable gluing handles. European Journal of Medicinal Chemistry (2026), 119034. DOI: 10.1016/j.ejmech.2026.119034.